Participated · Seed · Jul 2026

Accipiter Biosciences applies artificial-intelligence tools developed at the University of Washington’s Institute for Protein Design to engineer proteins capable of binding multiple cellular targets simultaneously. The company runs both partnered programs (including collaborations and license agreements with Pfizer and Kite Pharma) and internal drug-development programs, with a current focus on immunology-related conditions alongside a lead oncology program. Its Pfizer agreement included an upfront payment and the potential to earn over $330 million in milestones and royalties, and the Kite/Gilead collaboration is similarly structured. Accipiter launched in March 2023 and has grown its team to 22 employees, planning to expand to about 30 within the next six to twelve months. With the recent $10.5 million seed top-up (bringing total raised to about $23.2 million), the company intends to accelerate advancement of three to four programs into clinical trials versus its original plan of one or two.

Led · Series B · Jun 2026

Ona Therapeutics is a spin-off from IRB Barcelona and ICREA that develops precision-engineered antibody-drug conjugates (ADCs) to target treatment-resistant cancers. The company uses a proprietary, patient-driven discovery platform to identify tumor-specific antigens and epitopes that enable efficient internalization and targeted payload delivery. Its lead clinical program is ONA-255, initially focused on breast cancer, and it is also advancing ONA-389 targeting colorectal cancer. The company integrates target validation, antibody engineering, optimized payload selection and validated linker-payload technologies in its ADC development approach. Led by CEO Valerie Vanhooren, Ona plans to use the Series B proceeds to advance clinical development of its lead and second programs. The article does not disclose revenue, user metrics or a company valuation.

Participated · Series B · Sep 2025

ARTHEx Biotech is a clinical-stage company specializing in targeted RNA medicines that precisely modulate gene expression across skeletal muscle, heart and brain tissues. Its lead program, ATX-01, is an oleic-acid-conjugated anti-miR oligonucleotide designed to inhibit microRNA-23b and restore MBNL protein function in myotonic dystrophy type 1 (DM1); the drug is currently being evaluated in the randomized, placebo-controlled Phase I/IIa ArthemiR™ study. ATX-01 has secured Orphan Drug Designation in both the United States and Europe, as well as Rare Pediatric Disease Designation from the FDA. Preclinical data show the therapy increases MBNL production, reduces toxic DMPK mRNA and corrects spliceopathy in animal and cell models. Beyond DM1, ARTHEx is using its delivery platform to build a pipeline for additional muscular, CNS, cardiac and pulmonary diseases with high unmet need. The company’s headquarters are in Valencia, Spain, and it recently upsized its Series B financing to support preparation for a registrational study of ATX-01 and to broaden its pipeline. Including this round, the company has attracted backing from a consortium of European and U.S. life-science investors.

Participated · Series A · Sep 2025

Integra Therapeutics is a spin‑out from Pompeu Fabra University (founded in 2020) developing the FiCAT platform, which combines CRISPR‑Cas accuracy with an engineered piggyBac transposase to address payload size, stability, and accuracy limitations in gene therapy. The platform targets applications across genetic, oncological, and autoimmune diseases and is being used to advance next‑generation CAR‑T therapies. The company is also developing a first gene therapy candidate for a rare pediatric liver disease, supported by an EIC Accelerator grant. Integra plans to integrate new advances into FiCAT, expand cell engineering capabilities, and facilitate technology transfer to the pharmaceutical industry. The team intends to use new funding to support preclinical validation of CAR‑T programs and to scale its cell engineering operations. Leadership includes co‑founders Dr. Marc Güell and Dr. Avencia Sánchez‑Mejías; the company is based in Barcelona. Integra Therapeutics is a Barcelona‑based biotech spin‑off (founded 2020 from Pompeu Fabra University) developing FiCAT, a gene‑writing platform intended to overcome current limits on size, precision and stability. Its core product, FiCAT, targets ex vivo engineering of T cells and hematopoietic stem cells and systemic in vivo gene therapy using non‑viral lipid nanoparticle (LNP) delivery. The company plans to use initial funding to support pre‑marketing activities for cell therapy applications across rare diseases, autoimmune disorders and oncology. In parallel, Integra will generate proof‑of‑concept data for a first gene therapy aimed at a serious pediatric hepatic disease using systemic non‑viral delivery. Longer term, Integra intends to expand FiCAT to extra‑hepatic indications and to pursue licensing and co‑development partnerships to broaden patient access. The company is led by co‑founders Dr Marc Güell and Dr Avencia Sánchez‑Mejías. Integra Therapeutics develops next-generation gene writing tools and is advancing a gene writing platform called FiCAT to improve safety and efficacy of advanced therapies. The company targets prevention and treatment of genetic diseases and cancers with unmet medical needs. Co-founded by Marc Güell and Avencia Sánchez-Mejías, Integra is working toward a FiCAT platform prototype and preclinical validation. The planned preclinical work includes in vivo and ex vivo models. Financially, the company raised an additional €1.5m in seed funding in March 2022 following a €4.5m seed raise in December. The new investment includes participation from Columbus Venture Partners, which will place a representative on the board. Integra Therapeutics (Integra Tx) is a biotechnology spin-off from Pompeu Fabra University focused on creating next-generation gene writing tools to make advanced therapies safer and more effective. The company was founded in late 2020 based on technology developed in the Translational Synthetic Biology Lab led by Dr. Marc Güell and Avencia Sánchez-Mejías. Integra intends to complete a prototype of its gene writing platform and carry out preclinical validation using in vivo and ex vivo models. It plans to manage and expand its patent portfolio through 2022 and 2023. The company raised €4.5M in its first round of funding to support these development activities. After prototyping and preclinical work, Integra plans to open a Series A to seek regulatory approval and carry out clinical trials with patients.

Led · Series C · Apr 2025

deepull is a Barcelona, Spain-based medical diagnostics company focused on culture-free diagnostic solutions for sepsis and acute infections. It is developing the UllCORE BSI Test, an automated, walkaway system that uses molecular techniques to extract and detect microbial DNA directly from whole blood. The multiplex PCR test covers 95% of sepsis-causing pathogens, including bacteria and fungi, and detects antibiotic resistance genes, providing critical results in about one hour. deepull intends to use the €50M Series C proceeds to finalize clinical validation and expedite regulatory approval of its UllCORE diagnostic system. The company is led by CEO Jordi Carrera. The Series C included participation from multiple existing investors alongside the new lead investors. DeepUll is a medical technology company developing culture-free diagnostics for early identification of sepsis and other acute infections. Founded in 2020 in Barcelona by the founders of STAT-Dx, the company has assembled a team of globally recognized experts. Its sepsis product is designed to detect more than 250 pathogens and 15 resistance genes from 10 mL of blood in about one hour. The product also generates phenotypic antimicrobial susceptibility results in roughly eight hours without requiring a positive blood culture. Intended as a desktop, end-to-end automated device, it is designed for deployment in laboratories, emergency departments and ICUs. The company aims to improve patient outcomes and reduce unnecessary antimicrobial use; the recent Series B financing that reached €17M will support platform development and the path to market. DeepUll develops culture-free, affordable diagnostic solutions aimed at the early identification of sepsis and other acute infections. Its core product is an automated, desktop diagnostics platform designed to detect more than 250 pathogens and about 15 resistance genes in one hour from 10 mL of whole blood. The system produces phenotypic antimicrobial-susceptibility results in about eight hours without requiring a positive blood culture and is intended for deployment in laboratories, emergency rooms and ICUs. DeepUll’s platform includes end-to-end automation and leverages artificial intelligence to provide medical decision support across early recognition, precise diagnostics and therapy guidance. To accelerate development, DeepUll will expand its RD&I activities to bring the automated diagnostics device toward clinical use. The company was founded in 2020 in Barcelona by the founders of STAT-Dx. DeepUll develops culture-free diagnostic solutions for sepsis and acute infections. Its sepsis product is designed to detect more than 250 different pathogens and about 15 resistance genes in one hour starting from 10mL of whole blood. The product will generate phenotypic antimicrobial susceptibility results in about eight hours, without requiring a positive blood culture. It is planned as a desktop system with end-to-end automation, intended to be placed in any clinical setting. The company raised €13M in a Series B to progress the development of its sepsis recognition platform toward the market. DeepUll was founded by Jordi Carrera and Rafel Bru, who previously co-founded STAT-Dx (acquired by Qiagen in 2018), and is based in Barcelona, Spain. DeepUll is building a diagnostic platform that identifies pathogens and provides antibiograms in a few hours without prior culture, and incorporates patient immunological status and AI to predict sepsis onset and evolution. The system aims to enable earlier, precision therapeutic recommendations by combining pathogen detection with data-driven assessment of the patient’s immune and functional status. The company plans to validate the underlying technologies and build initial diagnostic units to demonstrate clinical utility. The funds raised in the announced round are intended to cover the financial needs for technology validation and the development of first devices. DeepUll was founded in 2019 by Jordi Carrera and Rafel Bru and is based in the Parc Científic de Barcelona. The team highlights prior entrepreneurial experience from selling STAT-Dx to QIAGEN and positions the product to address sepsis and antibiotic resistance at hospital scale.